Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

NCT01026974 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease

Interventions

BIOLOGICAL: rMenB
BIOLOGICAL: rMenB+OMV NZ

Sponsor

Novartis Vaccines